JP2014522850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522850A5 JP2014522850A5 JP2014519224A JP2014519224A JP2014522850A5 JP 2014522850 A5 JP2014522850 A5 JP 2014522850A5 JP 2014519224 A JP2014519224 A JP 2014519224A JP 2014519224 A JP2014519224 A JP 2014519224A JP 2014522850 A5 JP2014522850 A5 JP 2014522850A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- variable region
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 53
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 46
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 24
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 24
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504633P | 2011-07-05 | 2011-07-05 | |
| US61/504,633 | 2011-07-05 | ||
| US201161558945P | 2011-11-11 | 2011-11-11 | |
| US61/558,945 | 2011-11-11 | ||
| PCT/US2012/045235 WO2013006547A2 (en) | 2011-07-05 | 2012-07-02 | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017223241A Division JP2018070622A (ja) | 2011-07-05 | 2017-11-21 | 上皮成長因子受容体（ｅｇｆｒ）に対する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522850A JP2014522850A (ja) | 2014-09-08 |
| JP2014522850A5 true JP2014522850A5 (https=) | 2015-08-13 |
| JP6249945B2 JP6249945B2 (ja) | 2017-12-20 |
Family
ID=46682898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519224A Expired - Fee Related JP6249945B2 (ja) | 2011-07-05 | 2012-07-02 | 上皮成長因子受容体（ｅｇｆｒ）に対する抗体及びその使用 |
| JP2017223241A Withdrawn JP2018070622A (ja) | 2011-07-05 | 2017-11-21 | 上皮成長因子受容体（ｅｇｆｒ）に対する抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017223241A Withdrawn JP2018070622A (ja) | 2011-07-05 | 2017-11-21 | 上皮成長因子受容体（ｅｇｆｒ）に対する抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US8691231B2 (https=) |
| EP (2) | EP2729172B1 (https=) |
| JP (2) | JP6249945B2 (https=) |
| KR (1) | KR20140048230A (https=) |
| CN (1) | CN103781494B (https=) |
| AU (1) | AU2012279132B2 (https=) |
| BR (1) | BR112014000158A8 (https=) |
| CA (1) | CA2840088A1 (https=) |
| HK (1) | HK1197071A1 (https=) |
| IL (1) | IL229951B (https=) |
| MX (1) | MX350861B (https=) |
| TW (1) | TWI583700B (https=) |
| WO (1) | WO2013006547A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2566512A1 (en) | 2010-05-04 | 2013-03-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| CA2872018A1 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind egfr |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014028221A1 (en) | 2012-07-31 | 2014-02-20 | Crown Bioscience, Inc. | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
| KR101854003B1 (ko) * | 2013-07-02 | 2018-06-14 | 경희대학교 산학협력단 | 복수의 레이어를 포함하는 영상의 부호화 및 복호화 방법 |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| EP2955522A1 (en) * | 2014-06-13 | 2015-12-16 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | A method for monitoring the treatment of patients with tumors expressing EGFR |
| CA2983890A1 (en) * | 2015-04-24 | 2016-10-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| WO2017035482A1 (en) * | 2015-08-27 | 2017-03-02 | Merrimack Pharmaceuticals, Inc | Combination therapies for treatment of heregulin positive cancers |
| EP4647126A3 (en) | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| WO2017070475A1 (en) * | 2015-10-22 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies |
| WO2017070456A1 (en) * | 2015-10-22 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating cancer by administering a bispecific antibody antagonist of igf-ir and erbb3 and a combination of anti-egfr antibodies |
| WO2017070356A1 (en) * | 2015-10-23 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND MENTHODS OF TREATMENT THEREWITH |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| MX2018011109A (es) * | 2016-03-28 | 2018-11-09 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| US20170336392A1 (en) * | 2016-05-02 | 2017-11-23 | Emmanuel A. Theodorakis | Imaging methods to assess the efficacy of anticancer drugs in vitro cancer using spontaneously- forming spheroids |
| WO2018006785A1 (zh) * | 2016-07-05 | 2018-01-11 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| CA3054381A1 (en) * | 2017-02-22 | 2018-08-30 | University Of Saskatchewan | Egfr-binding agents and uses thereof |
| US11466096B2 (en) | 2017-03-17 | 2022-10-11 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| BR112019027729A2 (pt) * | 2017-06-27 | 2020-08-18 | Neuracle Science Co., Ltd | anticorpos anti-fam19a5 e seus usos |
| CN109402063B (zh) * | 2017-08-18 | 2020-11-24 | 河北省科学院生物研究所 | 抗猪血红蛋白杂交瘤细胞株及其单克隆抗体与应用 |
| US20200347140A1 (en) | 2017-08-30 | 2020-11-05 | Symphogen A/S | Compositions and methods for treating cancer with anti-egfr antibodies |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| AU2019235900B2 (en) * | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| WO2019207513A1 (en) | 2018-04-24 | 2019-10-31 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| WO2020138487A1 (ja) | 2018-12-28 | 2020-07-02 | 協和キリン株式会社 | ＴｆＲに結合するバイスペシフィック抗体 |
| CN110812479A (zh) * | 2019-11-18 | 2020-02-21 | 青海晨菲制药有限公司 | 没食子酸和egfr靶点抗体组合物及其在肺癌上应用 |
| US20230027739A1 (en) | 2021-05-10 | 2023-01-26 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| TWI877756B (zh) * | 2022-08-31 | 2025-03-21 | 中國醫藥大學 | 抗meEGFR抗體、其抗原結合片段及其用途 |
| CN120005727B (zh) * | 2025-01-03 | 2025-10-31 | 华南理工大学 | 一种用于研究胶质瘤car-t疗法的动态微流控芯片装置、制备方法及其应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
| TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| IT1303776B1 (it) | 1998-11-19 | 2001-02-23 | S I S S A Scuola Internaz Supe | Processo per la preparazione di genoteche, di polipeptidi utilizzandodette genoteche e i polipepti ottenuti. |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| KR100983997B1 (ko) | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
| AU2003251597A1 (en) * | 2002-06-19 | 2004-01-06 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| WO2004032961A1 (en) | 2002-10-10 | 2004-04-22 | Merck Patent Gmbh | Bispecific anti-erb-b antibodies and their use in tumor therapy |
| WO2004046386A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| BRPI0510716A (pt) | 2004-05-05 | 2007-11-20 | Merrimack Pharmaceuticals Inc | uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit |
| CA2599606A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| EP2089543B1 (en) | 2006-11-15 | 2020-07-01 | BioFire Diagnostics, LLC | High density self-contained biological analysis |
| TW200846362A (en) | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
| BRPI0808551B1 (pt) * | 2007-03-01 | 2022-04-05 | Symphogen A/S | Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende |
| WO2009030239A1 (en) | 2007-09-06 | 2009-03-12 | Genmab A/S | Novel methods and antibodies for treating cancer |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8159931B2 (en) | 2007-12-11 | 2012-04-17 | Broadcom Corporation | Orthogonal pilot code construction |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| NZ589143A (en) * | 2008-05-14 | 2012-02-24 | Genomic Health Inc | Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels |
| WO2010019952A2 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| DE102010014680A1 (de) | 2009-11-18 | 2011-08-18 | Evonik Degussa GmbH, 45128 | Zellen, Nukleinsäuren, Enzyme und deren Verwendung sowie Verfahren zur Herstellung von Sophorolipiden |
| RU2012148398A (ru) * | 2010-04-18 | 2014-05-27 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ |
| EP2566512A1 (en) | 2010-05-04 | 2013-03-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| MX2013010444A (es) | 2011-03-15 | 2014-03-21 | Merrimack Pharmaceuticals Inc | Superar la resistencia a inhibidores de la via erbb. |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| US20170314079A1 (en) | 2011-07-05 | 2017-11-02 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| EP2554551A1 (en) | 2011-08-03 | 2013-02-06 | Fundacio Institut mar d'Investigacions Médiques (IMIM) | Mutations in the epidermal growth factor receptor gene |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| CA2983890A1 (en) | 2015-04-24 | 2016-10-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
-
2012
- 2012-06-04 US US13/488,270 patent/US8691231B2/en not_active Expired - Fee Related
- 2012-07-02 JP JP2014519224A patent/JP6249945B2/ja not_active Expired - Fee Related
- 2012-07-02 EP EP12748078.8A patent/EP2729172B1/en not_active Not-in-force
- 2012-07-02 AU AU2012279132A patent/AU2012279132B2/en not_active Ceased
- 2012-07-02 WO PCT/US2012/045235 patent/WO2013006547A2/en not_active Ceased
- 2012-07-02 EP EP16173573.3A patent/EP3090759A1/en not_active Withdrawn
- 2012-07-02 CA CA2840088A patent/CA2840088A1/en not_active Abandoned
- 2012-07-02 HK HK14109561.4A patent/HK1197071A1/xx unknown
- 2012-07-02 MX MX2014000270A patent/MX350861B/es active IP Right Grant
- 2012-07-02 BR BR112014000158A patent/BR112014000158A8/pt not_active IP Right Cessation
- 2012-07-02 KR KR1020147002877A patent/KR20140048230A/ko not_active Ceased
- 2012-07-02 CN CN201280040289.9A patent/CN103781494B/zh not_active Expired - Fee Related
- 2012-07-04 TW TW101123962A patent/TWI583700B/zh not_active IP Right Cessation
-
2013
- 2013-12-17 IL IL229951A patent/IL229951B/en not_active IP Right Cessation
-
2014
- 2014-01-03 US US14/147,331 patent/US9226964B2/en not_active Expired - Fee Related
- 2014-02-14 US US14/181,307 patent/US20140170668A1/en not_active Abandoned
- 2014-04-30 US US14/266,387 patent/US20140234314A1/en not_active Abandoned
-
2015
- 2015-08-24 US US14/833,834 patent/US20160083800A1/en not_active Abandoned
- 2015-09-08 US US14/847,297 patent/US10072299B2/en not_active Expired - Fee Related
- 2015-09-08 US US14/847,304 patent/US9885087B2/en not_active Expired - Fee Related
- 2015-09-08 US US14/847,291 patent/US9902999B2/en not_active Expired - Fee Related
-
2017
- 2017-03-17 US US15/462,738 patent/US20170356049A1/en not_active Abandoned
- 2017-11-21 JP JP2017223241A patent/JP2018070622A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014522850A5 (https=) | ||
| JP2017519759A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2019510733A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2011046732A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2017512765A5 (https=) | ||
| JP2019501883A5 (https=) | ||
| JP2018534933A5 (https=) | ||
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| JP2015509947A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2017500057A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| JP2017500028A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2020502271A5 (https=) | ||
| JP2013506622A5 (https=) | ||
| JP2013519364A5 (https=) | ||
| JP2012525149A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2009521496A5 (https=) |